Marshall Protocol Knowledge Base - home:patients

Medical and Internet abbreviations

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

08.20.2017		current
Line 4:		Line 4:


-	The [[http://invention.swmed.edu/argh/\|ARGH Biomedical Acronym Resolver]] is a comprehensive resource for biomedical abbreviations.	+	The [[https://invention.swmed.edu/argh/\|ARGH Biomedical Acronym Resolver]] is a comprehensive resource for biomedical abbreviations.

	The following abbreviations are used on the Marshall Protocol study site.		The following abbreviations are used on the Marshall Protocol study site.
Line 222:		Line 222:
	Z – Zithromax\\		Z – Zithromax\\

		+	{{tag> resource}}



		+
		+	<nodisp>
	===== Notes and comments =====		===== Notes and comments =====

Line 231:		Line 234:

	* Legacy content		* Legacy content
-	* http://www.marshallprotocol.com/forum2/18.html e256	+	* https://www.marshallprotocol.com/forum2/18.html e256

	\\		\\

-	The title of this page is "medical abbreviations" ... however the content is a mix of medical and internet terms. --- //Joyful 2009/05/23 03:44//	+	The title of this page is "medical abbreviations" ... however the content is a mix of medical and internet terms. --- //Joyful 2009/05/23 03:44//</nodisp>

Assessing the published literature

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

Statistics on the Marshall Protocol

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

03.24.2019		current
Line 4:		Line 4:
	====== Statistics on the Marshall Protocol ======		====== Statistics on the Marshall Protocol ======

-	The primary function of the Marshall Protocol (MP) study site is to learn how the MP affects and improves the health of patients with a variety of inflammatory conditions. As of February 2009, there are about 1,000 patients who post in their progress reports on the MP study site. Many patients have recovered sufficiently to rejoin the work force, and subsequently become so busy that they no longer report progress. Autoimmunity Research Foundation is currently in the process of partnering with a hospital which has the resources necessary to manage a large-scale cohort study of the MP.	+	The primary function of the Marshall Protocol (MP) study site is to learn how the MP affects and improves the health of patients with a variety of inflammatory conditions. As of February 2009, there are about 1,000 patients who post in their progress reports on the MP study site. Most patients have recovered sufficiently to rejoin the work force, and subsequently become so busy that they no longer report progress. Autoimmunity Research Foundation is currently in the process of partnering with a hospital which has the resources necessary to manage a large-scale cohort study of the MP.

	===== Response rate =====		===== Response rate =====
Line 96:		Line 96:

	{{tag> resource}}		{{tag> resource}}
		+	<nodisp>
	===== Notes and comments =====		===== Notes and comments =====

Line 101:		Line 102:

	* Legacy content		* Legacy content
-	* http://www.marshallprotocol.com/forum32/2527.html f323	+	* https://www.marshallprotocol.com/forum32/2527.html f323
-	* http://www.marshallprotocol.com/forum32/4251.html f305	+	* https://www.marshallprotocol.com/forum32/4251.html f305
-		+	</nodisp>

Cost of the Marshall Protocol

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

10.13.2018		current
Line 11:		Line 11:
	===== Visits to a physician =====		===== Visits to a physician =====

-	<relatedarticle> [[home:starting:physician\|Working with a Marshall Protocol physician]] </article>	+	<relatedarticle> [[home:starting:physician\|Working with a physician]] </article>

	To do the MP, patients require a licensed physician, whose responsibility it is to monitor progress and prescribe the necessary medications. This cost of the physician depends on a couple factors:		To do the MP, patients require a licensed physician, whose responsibility it is to monitor progress and prescribe the necessary medications. This cost of the physician depends on a couple factors:
Line 41:		Line 41:
	===== Medication =====		===== Medication =====

-	There is some [[home:mp:olmesartan:buying#financial_help_for_buying_olmesartan_benicar\|financial help available for buying Benicar and other prescription medications]]. Benicar's own label, //[[http://www.sankyopharma.com/news/patientassistance.html\|Daiichi Sankyo]]//, sponsors one called the Open Care Program.	+	There is some [[home:mp:olmesartan:buying#financial_help_for_buying_olmesartan_benicar\|financial help available for buying Benicar and other prescription medications]]. Benicar's own label, //[[https://www.sankyopharma.com/news/patientassistance.html\|Daiichi Sankyo]]//, sponsors one called the Open Care Program.


Line 67:		Line 67:

	{{tag>resource Starting_the_Marshall_Protocol}}		{{tag>resource Starting_the_Marshall_Protocol}}
		+	<nodisp>
	===== Notes and comments =====		===== Notes and comments =====

Line 72:		Line 73:

	* Legacy content		* Legacy content
-	* http://www.marshallprotocol.com/forum32/8219.html f159	+	* https://www.marshallprotocol.com/forum32/8219.html f159
-	* http://www.marshallprotocol.com/view_topic.php?id=691&forum_id=2&jump_to=40306#p40306 e152	+	* https://www.marshallprotocol.com/view_topic.php?id=691&forum_id=2&jump_to=40306#p40306 e152
-		+	</nodisp>

Glossary

anonymous@undisclosed.example.com (Anonymous) — Sat, 13 Oct 2018 10:31:46 +0000

10.21.2016		current
Line 89:		Line 89:


-	{{tag>Simple_Explanations Starting_the_Marshall_Protocol}}	+	{{tag>resource Simple_Explanations Starting_the_Marshall_Protocol}}

Confronting uncertainty about the Marshall Protocol

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

Length of the Marshall Protocol

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

Introduction to the Marshall Pathogenesis

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

01.27.2016		current
Line 41:		Line 41:


-	{{tag>Simple_Explanations}}	+	{{tag>Simple_Explanations resource}}

		+	<nodisp>
	===== Notes and comments =====		===== Notes and comments =====

Line 50:		Line 51:
	*		*

-	===== References =====	+	===== References =====</nodisp>

Patient interviews

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

07.14.2020		current
Line 2:		Line 2:

	//N.B. the below recorded interviews are no longer available online//		//N.B. the below recorded interviews are no longer available online//
		+
		+	You may be interested in https://microbeminded.com/author/amyproal/

	However, dozens of different patients have shared their stories of recovery on the [[https://www.marshallprotocol.com/\|Marshall protocol Study site]].		However, dozens of different patients have shared their stories of recovery on the [[https://www.marshallprotocol.com/\|Marshall protocol Study site]].
Line 21:		Line 23:
	sarcoidosis, bladder cancer		sarcoidosis, bladder cancer

-	Read the [[http://bacteriality.com/2008/07/18/interview24/\|interview]]	+	Read the [[https://bacteriality.com/2008/07/18/interview24/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 34:		Line 36:
	lupus, Sjogren’s Syndrome		lupus, Sjogren’s Syndrome

-	Read the [[http://bacteriality.com/2008/07/02/interview23/\|interview]]	+	Read the [[https://bacteriality.com/2008/07/02/interview23/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 48:		Line 50:
	diabetes, sarcoidosis, irritable bowel syndrome		diabetes, sarcoidosis, irritable bowel syndrome

-	Read the [[http://bacteriality.com/2008/06/19/interview22/\|interview]]	+	Read the [[https://bacteriality.com/2008/06/19/interview22/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 61:		Line 63:
	sarcoidosis, rheumatoid arthritis		sarcoidosis, rheumatoid arthritis

-	Read the [[http://bacteriality.com/2008/06/03/interview21/\|interview]]	+	Read the [[https://bacteriality.com/2008/06/03/interview21/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 74:		Line 76:
	sarcoidosis, cat scratch fever, restless leg syndrome		sarcoidosis, cat scratch fever, restless leg syndrome

-	Read the [[http://bacteriality.com/2007/11/19/interview13/\|interview]]	+	Read the [[https://bacteriality.com/2007/11/19/interview13/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 90:		Line 92:
	chronic fatigue syndrome (CFS), multiple chemical sensitivities		chronic fatigue syndrome (CFS), multiple chemical sensitivities

-	Read the [[http://bacteriality.com/2008/05/23/interview20/\|interview]]	+	Read the [[https://bacteriality.com/2008/05/23/interview20/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 117:		Line 119:
	autism, ADHD, depression, severe anxiety, chronic fatigue syndrome (CFS)		autism, ADHD, depression, severe anxiety, chronic fatigue syndrome (CFS)

-	Read the [[http://bacteriality.com/2008/03/15/interview18/\|interview]]	+	Read the [[https://bacteriality.com/2008/03/15/interview18/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 136:		Line 138:
	sarcoidosis		sarcoidosis

-	Read the [[http://bacteriality.com/2007/11/17/interview11/\|interview]]	+	Read the [[https://bacteriality.com/2007/11/17/interview11/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 166:		Line 168:
	neurosarcoidosis, systemic sarcoidosis; spasticity, myasthenia, CNS dysfunction, joint pain, pulmonary, splenic and cardiac involvement		neurosarcoidosis, systemic sarcoidosis; spasticity, myasthenia, CNS dysfunction, joint pain, pulmonary, splenic and cardiac involvement

-	Read the [[http://bacteriality.com/2008/03/02/interview17/\|interview]]	+	Read the [[https://bacteriality.com/2008/03/02/interview17/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 180:		Line 182:
	chronic borreliosis ("Lyme"), multiple chemical sensitivities, chronic spinal inflammation, peripheral neuropathy		chronic borreliosis ("Lyme"), multiple chemical sensitivities, chronic spinal inflammation, peripheral neuropathy

-	Read the [[http://bacteriality.com/2007/12/28/interview14/\|interview]]	+	Read the [[https://bacteriality.com/2007/12/28/interview14/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 195:		Line 197:
	sarcoidosis of the heart, coronary artery disease, atrial fibrillation		sarcoidosis of the heart, coronary artery disease, atrial fibrillation

-	Read the [[http://bacteriality.com/2008/01/18/interview15/\|interview]]	+	Read the [[https://bacteriality.com/2008/01/18/interview15/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 211:		Line 213:
	Lyme disease, irritable bowel syndrome/ulcerative colitis, radiculitis		Lyme disease, irritable bowel syndrome/ulcerative colitis, radiculitis

-	Read the [[http://bacteriality.com/2008/02/17/interview16/\|interview]]	+	Read the [[https://bacteriality.com/2008/02/17/interview16/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 226:		Line 228:
	Post Treatment Lyme Disease Syndrome (PTLDS)		Post Treatment Lyme Disease Syndrome (PTLDS)

-	Read the [[http://bacteriality.com/2008/03/31/interview19/\|interview]]	+	Read the [[https://bacteriality.com/2008/03/31/interview19/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 243:		Line 245:
	sarcoidosis (Hedfort Syndrome), uveitis		sarcoidosis (Hedfort Syndrome), uveitis

-	Read the [[http://bacteriality.com/2007/11/19/interview12\|interview]]	+	Read the [[https://bacteriality.com/2007/11/19/interview12\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 257:		Line 259:
	rheumatoid arthritis, dyslexia		rheumatoid arthritis, dyslexia

-	Read the [[http://bacteriality.com/2007/09/01/interview2/\|interview]]	+	Read the [[https://bacteriality.com/2007/09/01/interview2/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 276:		Line 278:
	sarcoidosis, fibromyalgia, chronic fatigue syndrome (CFS)		sarcoidosis, fibromyalgia, chronic fatigue syndrome (CFS)

-	Read the [[http://bacteriality.com/2007/11/08/interview8//\|interview]]	+	Read the [[https://bacteriality.com/2007/11/08/interview8//\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 290:		Line 292:
	sarcoidosis		sarcoidosis

-	Read the [[http://bacteriality.com/2007/11/04/interview7/\|interview]]	+	Read the [[https://bacteriality.com/2007/11/04/interview7/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 303:		Line 305:
	chronic fatigue syndrome (CFS), depression, food sensitivities, insomnia		chronic fatigue syndrome (CFS), depression, food sensitivities, insomnia

-	Read the [[http://bacteriality.com/2007/11/10/interview10/\|interview]]	+	Read the [[https://bacteriality.com/2007/11/10/interview10/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 318:		Line 320:
	Lyme, myoclonus		Lyme, myoclonus

-	Read the [[http://bacteriality.com/2007/10/28/interview6/\|interview]]	+	Read the [[https://bacteriality.com/2007/10/28/interview6/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 331:		Line 333:
	Lyme, //Babesia//		Lyme, //Babesia//

-	Read the [[http://bacteriality.com/2007/09/22/interview3/\|interview]]	+	Read the [[https://bacteriality.com/2007/09/22/interview3/\|interview]]

	<html></div></div></html>		<html></div></div></html>
Line 347:		Line 349:
	sarcoidosis, psoriasis, insomnia, kidney stones		sarcoidosis, psoriasis, insomnia, kidney stones

-	Read the [[http://bacteriality.com/2007/08/10/interview1/\|interview]]	+	Read the [[https://bacteriality.com/2007/08/10/interview1/\|interview]]

	<html></div></div>		<html></div></div>
Line 362:		Line 364:


		+	<nodisp>
	===== Notes and comments =====		===== Notes and comments =====

Line 377:		Line 380:
	sarcoidosis, obsessive compulsive disorder, uveitis		sarcoidosis, obsessive compulsive disorder, uveitis

-	Read the [[http://bacteriality.com/2007/11/10/interview9\|interview]]	+	Read the [[https://bacteriality.com/2007/11/10/interview9\|interview]]

	<html></div></div></html>		<html></div></div></html>


-	[[http://www.marshallprotocol.com/forum30/7473.html\|Other people who are doing well]]	+	[[https://www.marshallprotocol.com/forum30/7473.html\|Other people who are doing well]]</nodisp>

Introduction to the Marshall Protocol

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

06.24.2019		current
Line 5:		Line 5:


-	The Marshall Protocol, sometimes referred to as the MP, was developed by a team led by Trevor Marshall, PhD, as an antimicrobial treatment for chronic inflammatory diseases. Most diseases of unknown cause are chronic inflammatory diseases, and almost 100% of patients with these diseases have responded to the treatment. On this site and others, chronic inflammatory diseases are sometimes referred to as the Th1 diseases.	+	The Marshall Protocol, sometimes referred to as the MP, was developed by a team led by Trevor Marshall, PhD, as an antimicrobial treatment for chronic inflammatory diseases. Most diseases of unknown cause are chronic inflammatory diseases, and over 85% of patients with these diseases have responded to the treatment. On this site and others, chronic inflammatory diseases are sometimes referred to as the Th1 diseases.

	Treatment on the MP requires a [[home:patients:mp_duration\|number of years]] to complete, but the exact duration is determined by degree of illness and any unavoidable immune suppressants to which the patient is exposed.		Treatment on the MP requires a [[home:patients:mp_duration\|number of years]] to complete, but the exact duration is determined by degree of illness and any unavoidable immune suppressants to which the patient is exposed.
Line 110:		Line 110:


		+	<nodisp>
	===== Notes and comments =====		===== Notes and comments =====

Line 118:		Line 119:
	*		*
	*		*
-	===== References =====	+	===== References ===== </nodisp>

Tips for using the Marshall Protocol Knowledge Base

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

12.16.2018		current
Line 8:		Line 8:
	- At the top of each article, is the "You are here" section, which allows you see how a given article fits into the Knowledge Base hierarchy. For example: "Home > Non-MP treatments > Anti-TNF drugs."		- At the top of each article, is the "You are here" section, which allows you see how a given article fits into the Knowledge Base hierarchy. For example: "Home > Non-MP treatments > Anti-TNF drugs."
	- The Knowledge Base is divided into sections. Sometimes a section is covered in greater detail in another article. In these cases, the italicized text below the section header reads: "Main article."		- The Knowledge Base is divided into sections. Sometimes a section is covered in greater detail in another article. In these cases, the italicized text below the section header reads: "Main article."
-	- At the bottom of some articles are links to records for peer-reviewed published research appearing in PubMed.	+	- At the bottom of some articles are links to records for peer-reviewed published research appearing in [[https://www.ncbi.nlm.nih.gov/pubmed/?\|PubMed ]].
	- At the end of each article are keywords (also known as tags) that have been applied to an article. Clicking on a link for a keyword will take you to a list of links to related articles.		- At the end of each article are keywords (also known as tags) that have been applied to an article. Clicking on a link for a keyword will take you to a list of links to related articles.
	- Links that have a world icon are to sites that are outside the Knowledge Base or the Autoimmunity Research Foundation site.		- Links that have a world icon are to sites that are outside the Knowledge Base or the Autoimmunity Research Foundation site.
Line 18:		Line 18:


-	===== Notes and comments =====	+	<nodisp>
		+	===== Notes and comments =====</nodisp>

08.01.2019		current
Line 26:		Line 26:
	<blockquote>We as scientists are very good at studying what we know. But the unknown is out of reach, and what it may take... is someone who just has what might seem like a crazy idea, but the means to pursue it, and find that there are new links between the human microbiome, and diseases that today we don't really think of as having any underlying microbiological component.		<blockquote>We as scientists are very good at studying what we know. But the unknown is out of reach, and what it may take... is someone who just has what might seem like a crazy idea, but the means to pursue it, and find that there are new links between the human microbiome, and diseases that today we don't really think of as having any underlying microbiological component.

-	//Claire Fraser-Liggett, Director of the Institute for Genome Sciences at the University of Maryland, [[http://www.bbc.co.uk/programmes/b011jv8r\|BBC Radio 4 program about the Human Microbiome]]//	+	//Claire Fraser-Liggett, Director of the Institute for Genome Sciences at the University of Maryland, [[https://www.bbc.co.uk/programmes/b011jv8r\|BBC Radio 4 program about the Human Microbiome]]//
	</blockquote>		</blockquote>

Line 70:		Line 70:
	Another common source of questions is recent studies. PubMed has tens of millions of studies. Some of them, many in fact, seem to contradict the conclusions put forth in the Knowledge Base or in the ARF research team's published papers. Often, a critical thinker may be able to apply the evidence and criticisms in the Knowledge Base to a study and make sense of it.		Another common source of questions is recent studies. PubMed has tens of millions of studies. Some of them, many in fact, seem to contradict the conclusions put forth in the Knowledge Base or in the ARF research team's published papers. Often, a critical thinker may be able to apply the evidence and criticisms in the Knowledge Base to a study and make sense of it.

-	An example: one study concluded that vitamin D might lower the incidence of colorectal cancer.(({{pubmed>long:17556697}})) A critical thinker might realize that the study was only for four years and might even be able to find studies over a longer period, which contradicted the original study's findings. See (({{pubmed>long:18065602}})), (({{pubmed>long:17991672}})), (({{pubmed>long:18326620}})), (({{pubmed>long:18326621}})) and select OXFORD//academic// to read the comments.	+	An example: one study concluded that vitamin D might lower the incidence of colorectal cancer.(({{pmid>long:17556697}})) A critical thinker might realize that the study was only for four years and might even be able to find studies over a longer period, which contradicted the original study's findings. See (({{pmid>long:18065602}})), (({{pmid>long:17991672}})), (({{pmid>long:18326620}})), (({{pmid>long:18326621}})) and select OXFORD//academic// to read the comments.

-	Using statistical inferences, John P. A. Ioannidis concluded in the prestigious journal //PLoS Medicine// that half of published research must be wrong.(({{pubmed>long:16060722}})) The arguments of that paper are beyond the scope of this article; but in grappling with a confusing study, it's seriously worth considering how Ioannidis could be right.	+	Using statistical inferences, John P. A. Ioannidis concluded in the prestigious journal //PLoS Medicine// that half of published research must be wrong.(({{pmid>long:16060722}})) The arguments of that paper are beyond the scope of this article; but in grappling with a confusing study, it's seriously worth considering how Ioannidis could be right.

-	Karhausen wrote(({{pubmed>long:11080970}})), "Actually, there is no experience of causation: events do not wear their causal credentials on their faces." Many of the statements a reader sees in the context of a scientific paper is dependent on interpretation.	+	Karhausen wrote(({{pmid>long:11080970}})), "Actually, there is no experience of causation: events do not wear their causal credentials on their faces." Many of the statements a reader sees in the context of a scientific paper is dependent on interpretation.

	The point of the MP is that [[assessing_literature\|several of those key interpretations are wrong]].		The point of the MP is that [[assessing_literature\|several of those key interpretations are wrong]].
Line 102:		Line 102:
	<blockquote>Researchers have estimated that 60-80 percent of microbial infections in the body are caused by bacteria growing as a biofilm – as opposed to planktonic (free-floating) bacteria</blockquote>		<blockquote>Researchers have estimated that 60-80 percent of microbial infections in the body are caused by bacteria growing as a biofilm – as opposed to planktonic (free-floating) bacteria</blockquote>

-	This includes sub-clinical or undiagnosed conditions which were building up unnoticed. In my case in the second year I had flare-up followed by disappearance of symptoms which I formerly thought to be normal aging.	+	This includes sub-clinical or undiagnosed conditions which were building up unnoticed. In my case by the second year I had flare-ups followed by disappearance of symptoms which I formerly thought to be normal aging.

	When MP is maintained for many years, the recovering immune system is dealing with [[home:pathogenesis:microbiota:biofilm\|biofilm]].		When MP is maintained for many years, the recovering immune system is dealing with [[home:pathogenesis:microbiota:biofilm\|biofilm]].
Line 117:		Line 117:
	{{tag> resource Resources_for_Physicians research}}		{{tag> resource Resources_for_Physicians research}}

		+	<nodisp>
	===== Notes and comments =====		===== Notes and comments =====

Line 124:		Line 125:

	<blockquote>		<blockquote>
-	[[http://www.the-scientist.com/2010/12/1/32/1/\|Evidence: A Seductive but Slippery Concept]]	+	[[https://www.the-scientist.com/2010/12/1/32/1/\|Evidence: A Seductive but Slippery Concept]]
	Medical guidelines based on so-called scientific evidence are not a panacea.		Medical guidelines based on so-called scientific evidence are not a panacea.

Line 136:		Line 137:

	* Legacy content		* Legacy content
-	* http://www.marshallprotocol.com/forum32/3163.html#p28099 f274	+	* https://www.marshallprotocol.com/forum32/3163.html#p28099 f274
-	* http://www.marshallprotocol.com/forum32/8533.html f146	+	* https://www.marshallprotocol.com/forum32/8533.html f146
-	* http://www.marshallprotocol.com/view_topic.php?id=4142&forum_id=37&jump_to=91203#p91203 s155	+	* https://www.marshallprotocol.com/view_topic.php?id=4142&forum_id=37&jump_to=91203#p91203 s155


-	===== References =====	+	===== References =====</nodisp>

09.01.2019		current
Line 23:		Line 23:
	==== Similarity of the MP to anti-tuberculosis treatments ====		==== Similarity of the MP to anti-tuberculosis treatments ====

-	The range of time it takes seriously ill patients to recover on the MP is not entirely without precedent in medicine. The preferred regimen for the treatment of latent tuberculosis infection is 9 months of isoniazid.(({{pubmed>long:15941808}})) By contrast, that is only a single genus as opposed to a [[home:pathogenesis:microbiota\|metagenomic microbiota]]. Note that both treatments are intended to kill intracellular pathogens. It's also worth noting that recovery from tuberculosis also involves an immunopathological-type reaction.(({{pubmed>long:18600241}}))	+	The range of time it takes seriously ill patients to recover on the MP is not entirely without precedent in medicine. The preferred regimen for the treatment of latent tuberculosis infection is 9 months of isoniazid.(({{pmid>long:15941808}})) By contrast, that is only a single genus as opposed to a [[home:pathogenesis:microbiota\|metagenomic microbiota]]. Note that both treatments are intended to kill intracellular pathogens. It's also worth noting that recovery from tuberculosis also involves an immunopathological-type reaction.(({{pmid>long:18600241}}))

	===== Factors influencing length of treatment =====		===== Factors influencing length of treatment =====
Line 76:		Line 76:

	===== After completion of the Marshall Protocol =====		===== After completion of the Marshall Protocol =====
		+
		+	<relatedarticle> [[home:food:aim_health\|Aiming at health]] </article>

	To a large extent, patients who have completed the Marshall Protocol can return to a normal life with the following modifications:		To a large extent, patients who have completed the Marshall Protocol can return to a normal life with the following modifications:
Line 81:		Line 83:
	* light – Although suntanning is not an option, veterans of the MP may choose to expose their eyes and skin to increasing amounts of light. A word of caution: some patients in later stages of treatment may experience a [[home:mp:stages:stagefive\|Stage Five reaction]] when exposed to too much light. To limit the possibility of a severe immunopathological reaction, always increase light exposure (and exercise) gradually. Also, be aware that sometimes an increase in symptoms from light may begin one or two days after exposure and last for several days or even longer.		* light – Although suntanning is not an option, veterans of the MP may choose to expose their eyes and skin to increasing amounts of light. A word of caution: some patients in later stages of treatment may experience a [[home:mp:stages:stagefive\|Stage Five reaction]] when exposed to too much light. To limit the possibility of a severe immunopathological reaction, always increase light exposure (and exercise) gradually. Also, be aware that sometimes an increase in symptoms from light may begin one or two days after exposure and last for several days or even longer.
	* radio frequency radiating technology - prudent use within household, setting cell phones to Airplane mode when not in use, switching commputer modem off at bed time, measuring and avoiding exposure in other places whenever possible.		* radio frequency radiating technology - prudent use within household, setting cell phones to Airplane mode when not in use, switching commputer modem off at bed time, measuring and avoiding exposure in other places whenever possible.
-	* antibiotics – In later stages of the MP, the immune system is self-sustaining and can eradicate bacteria without antibiotics. However, there is no harm in using a few weeks' worth of MP antibiotics as an annual checkup in order to see if they can generate immunopathology.	+	* antibiotics – The recovering immune system is self-sustaining and will eradicate bacteria when only Olmesartan is taken. However, there is no harm in using a few weeks' worth of MP antibiotics as an annual checkup - to see if they can generate immunopathology.
	* olmesartan (Benicar) – In later stages of the MP, the Vitamin D Receptor, which controls key components of innate immunity, is properly working again and is activated even in the absence of olmesartan. However, olmesartan is still essential to palliate symptoms and protect organs from systemic immunopathology.		* olmesartan (Benicar) – In later stages of the MP, the Vitamin D Receptor, which controls key components of innate immunity, is properly working again and is activated even in the absence of olmesartan. However, olmesartan is still essential to palliate symptoms and protect organs from systemic immunopathology.
	* laboratory tests – Various tests are expected to come in range:		* laboratory tests – Various tests are expected to come in range:
Line 94:		Line 96:
	{{tag>Starting_the_Marshall_Protocol resource}}		{{tag>Starting_the_Marshall_Protocol resource}}

		+	<nodisp>
	===== Notes and comments =====		===== Notes and comments =====

Line 99:		Line 102:

	* Legacy content		* Legacy content
-	* [[http://www.marshallprotocol.com/view_topic.php?id=1263&forum_id=32&jump_to=36589#p36589]] f16	+	* [[https://www.marshallprotocol.com/view_topic.php?id=1263&forum_id=32&jump_to=36589#p36589]] f16
-	* [[http://www.marshallprotocol.com/forum32/1085.html#p42269]] f181	+	* [[https://www.marshallprotocol.com/forum32/1085.html#p42269]] f181
-	* [[http://www.marshallprotocol.com/view_topic.php?id=1085&forum_id=32&jump_to=52849#p52849]] f182	+	* [[https://www.marshallprotocol.com/view_topic.php?id=1085&forum_id=32&jump_to=52849#p52849]] f182
-	* [[http://www.marshallprotocol.com/forum32/1304.html]] f342	+	* [[https://www.marshallprotocol.com/forum32/1304.html]] f342
-	* [[http://www.marshallprotocol.com/view_topic.php?id=1085&forum_id=32&jump_to=73778#p73778]] f185	+	* [[https://www.marshallprotocol.com/view_topic.php?id=1085&forum_id=32&jump_to=73778#p73778]] f185
-	* [[http://www.marshallprotocol.com/view_topic.php?id=1085&forum_id=32&jump_to=81100#p81100]] f186	+	* [[https://www.marshallprotocol.com/view_topic.php?id=1085&forum_id=32&jump_to=81100#p81100]] f186
-	* [[http://www.marshallprotocol.com/view_topic.php?id=1085&forum_id=32&jump_to=85306#p85306]] f187	+	* [[https://www.marshallprotocol.com/view_topic.php?id=1085&forum_id=32&jump_to=85306#p85306]] f187
-	* [[http://www.marshallprotocol.com/forum32/2495.html#p33642]] f226	+	* [[https://www.marshallprotocol.com/forum32/2495.html#p33642]] f226



-	===== References =====	+	===== References =====</nodisp>

09.01.2019		current
Line 1:		Line 1:
	====== Assessing the published literature ======		====== Assessing the published literature ======
-		+
-	<relatedarticles> [[home:patients:grappling_uncertainty\|Grappling with uncertainty about the Marshall Protocol]], [[home:pathogenesis:vitamind:correlation\|Mistaking correlation for causation]] </article>	+	<relatedarticles> [[home:patients:assessing_literature:in_vitro_studies\|Differences between in vitro, in vivo, and in silico studies]], [[home:patients:grappling_uncertainty\|Grappling with uncertainty about the Marshall Protocol]], [[home:pathogenesis:vitamind:correlation\|Mistaking correlation for causation]] </article>

	Though well-grounded in molecular and clinical data, the conclusions offered by Marshall Protocol researchers are sometimes met with skepticism by clinicians and fellow researchers. Some wonder how the MP science could be valid, given the existence of seemingly contradicting evidence.		Though well-grounded in molecular and clinical data, the conclusions offered by Marshall Protocol researchers are sometimes met with skepticism by clinicians and fellow researchers. Some wonder how the MP science could be valid, given the existence of seemingly contradicting evidence.
Line 7:		Line 7:
	Researchers who work with Autoimmunity Research Foundation (ARF) take no special pride in arguing that the nature of chronic disease is different than most clinicians and researchers have imagined. Indeed, it makes matters more difficult: the less familiar a conclusion is, the harder it is to persuade someone of its validity.		Researchers who work with Autoimmunity Research Foundation (ARF) take no special pride in arguing that the nature of chronic disease is different than most clinicians and researchers have imagined. Indeed, it makes matters more difficult: the less familiar a conclusion is, the harder it is to persuade someone of its validity.

-	Using statistical inferences, John P. A. Ioannidis concluded in the prestigious journal //PLoS Medicine// that half of published research must be wrong.(({{pubmed>long:16060722}})) In grappling with a confusing study or even a field of study, it's seriously worth considering how Ioannidis could be right.	+	Using statistical inferences, John P. A. Ioannidis concluded in the prestigious journal //PLoS Medicine// that half of published research must be wrong.(({{pmid>long:16060722}})) In grappling with a confusing study or even a field of study, it's seriously worth considering how Ioannidis could be right.
	===== Problematic conclusions about human biology =====		===== Problematic conclusions about human biology =====

Line 18:		Line 18:
	-Diseases and symptoms of disease may share a common pathology and are [[home:pathogenesis:th1spectrum\|part of a single disorder]]. Although patients who become infected with the Th1 pathogens are given a variety of diagnoses, there are often no clear-cut distinctions between one disease and the next. Rather, symptoms frequently overlap, creating a spectrum of illness in which diseases are more connected to one another than mutually exclusive disease states. One significant piece of evidence for this is the high rate of [[home:pathogenesis:familial_aggregation\|familial aggregation]].		-Diseases and symptoms of disease may share a common pathology and are [[home:pathogenesis:th1spectrum\|part of a single disorder]]. Although patients who become infected with the Th1 pathogens are given a variety of diagnoses, there are often no clear-cut distinctions between one disease and the next. Rather, symptoms frequently overlap, creating a spectrum of illness in which diseases are more connected to one another than mutually exclusive disease states. One significant piece of evidence for this is the high rate of [[home:pathogenesis:familial_aggregation\|familial aggregation]].
	-The era of specialization has reduced the level of interdisciplinary cooperation and consequently the ability for clinicians to appreciate the underlying connection among diseases.		-The era of specialization has reduced the level of interdisciplinary cooperation and consequently the ability for clinicians to appreciate the underlying connection among diseases.
-	-The existence of a blood-brain barrier has been historically touted as a reason why microbes could not possibly have caused any number of neurological diseases. However, with the accumulation of additional evidence, this concept has progressively lost meaning.(({{pubmed>long:18604221}}))	+	-The existence of a blood-brain barrier has been historically touted as a reason why microbes could not possibly have caused any number of neurological diseases. However, with the accumulation of additional evidence, this concept has progressively lost meaning.(({{pmid>long:18604221}}))
	-[[home:patients:assessing_literature:animal_models\|Animal models]] do not always accurately represent human biology. In fact, murine (mouse) models are particularly problematic as the murine Vitamin D Receptor is not analogous to the human Vitamin D Receptor in [[home:publications:marshall_days_of_molecular_medicine_2008\|some key respects]].		-[[home:patients:assessing_literature:animal_models\|Animal models]] do not always accurately represent human biology. In fact, murine (mouse) models are particularly problematic as the murine Vitamin D Receptor is not analogous to the human Vitamin D Receptor in [[home:publications:marshall_days_of_molecular_medicine_2008\|some key respects]].
	-Only certain bacteria grow in an //[[.:assessing_literature:in_vitro_studies#in_vitro_studies\|in vitro]]// environment. Many fastidious forms of bacteria can only grow in the conditions offered by the human body.		-Only certain bacteria grow in an //[[.:assessing_literature:in_vitro_studies#in_vitro_studies\|in vitro]]// environment. Many fastidious forms of bacteria can only grow in the conditions offered by the human body.
Line 29:		Line 29:
	The process by which studies are designed and research is interpreted and shared has a number of liabilities.		The process by which studies are designed and research is interpreted and shared has a number of liabilities.

-	-One of the basic assumptions underlying many genome-wide association studies has been that the genetic makeup of all an individuals’ cells is essentially the same. In the vast majority of genetic studies to date, researchers have assumed that in sequencing DNA isolated from blood would reveal the genetic makeup of diseased tissues as well. This supposition was convenient: except for cancer, samples of diseased tissue are difficult or even impossible to take from living patients.(({{pubmed>long:19514060}})) However, recent evidence has emerged that the genes of at least some cells from the blood and tissue do not match genetically,(({{pubmed>long:19514060}})) meaning that ambitious and expensive genome-wide association studies may prove to have been essentially flawed from the outset.	+	-One of the basic assumptions underlying many genome-wide association studies has been that the genetic makeup of all an individuals’ cells is essentially the same. In the vast majority of genetic studies to date, researchers have assumed that in sequencing DNA isolated from blood would reveal the genetic makeup of diseased tissues as well. This supposition was convenient: except for cancer, samples of diseased tissue are difficult or even impossible to take from living patients.(({{pmid>long:19514060}})) However, recent evidence has emerged that the genes of at least some cells from the blood and tissue do not match genetically,(({{pmid>long:19514060}})) meaning that ambitious and expensive genome-wide association studies may prove to have been essentially flawed from the outset.
-	-Science is often not objective.(({{pubmed>long:7728037}})) The choice of research questions, the methods to collect and analyze data, and the interpretation of results all reflect the worldview of the investigator.(({{pubmed>long:12016246}})) Investigators often overemphasize the importance of their findings and the quality of their work and choose interpretations that will enhance chances of success of obtaining funds from granting bodies.	+	-Science is often not objective.(({{pmid>long:7728037}})) The choice of research questions, the methods to collect and analyze data, and the interpretation of results all reflect the worldview of the investigator.(({{pmid>long:12016246}})) Investigators often overemphasize the importance of their findings and the quality of their work and choose interpretations that will enhance chances of success of obtaining funds from granting bodies.
-	-Other serious conflicts of interest arise when for-profit organizations, such as device, biotechnology, and pharmaceutical companies, provide funds for conducting research, consulting, and attending scientific meetings. In the past 20 years, there has been an 8-fold increase in the number of trials for which authors declare industry affiliation.(({{pubmed>long:14982982}})) For example, one of the chief vitamin D researchers also sells a product containing vitamin D. Investigators accepting funds risk conflicts of interest. Even more problematic, they may cede their right to directly supervise data collection, participate in or supervise data analysis, and write the research reports to which their name is attached.(({{pubmed>long: 12123411}})) (({{pubmed>long:11556304}})) (({{pubmed>long:10816196}}))	+	-Other serious conflicts of interest arise when for-profit organizations, such as device, biotechnology, and pharmaceutical companies, provide funds for conducting research, consulting, and attending scientific meetings. In the past 20 years, there has been an 8-fold increase in the number of trials for which authors declare industry affiliation.(({{pmid>long:14982982}})) For example, one of the chief vitamin D researchers also sells a product containing vitamin D. Investigators accepting funds risk conflicts of interest. Even more problematic, they may cede their right to directly supervise data collection, participate in or supervise data analysis, and write the research reports to which their name is attached.(({{pmid>long: 12123411}})) (({{pmid>long:11556304}})) (({{pmid>long:10816196}}))
	-Observational epidemiological studies are [[home:pathogenesis:vitamind:observational_bias\|compromised by bias]] inherent to the design of the studies themselves. It is arguably impossible to sufficiently control the socioeconomic factors, which drive a person to participate in a therapy or take a supplement. Patients who take drugs or supplements, as recommended by experts, are more likely to have better education, better access to health care, etc.		-Observational epidemiological studies are [[home:pathogenesis:vitamind:observational_bias\|compromised by bias]] inherent to the design of the studies themselves. It is arguably impossible to sufficiently control the socioeconomic factors, which drive a person to participate in a therapy or take a supplement. Patients who take drugs or supplements, as recommended by experts, are more likely to have better education, better access to health care, etc.
-	-While much excitement has been generated surrounding evidence-based medicine, internal documents from the pharmaceutical industry suggest that the publicly available evidence base may not accurately represent the underlying data regarding its products.((Spielmans, G. and P. Parry [[http://tritolonen.fi/files/pdf/SpielmansParry.pdf\|From Evidence-based Medicine to Marketing-based Medicine: Evidence from Internal Industry Documents.]] 2010. //Journal of Bioethical Inquiry//.)) Publication or reporting bias, or the tendency not to publish negative results, increases the likelihood that the literature's descriptions of a therapy's efficacy are erroneous and decreases the likelihood that adverse effects are fully reported.(({{pubmed>long:20388211}}))	+	-While much excitement has been generated surrounding evidence-based medicine, internal documents from the pharmaceutical industry suggest that the publicly available evidence base may not accurately represent the underlying data regarding its products.((Spielmans, G. and P. Parry [[https://tritolonen.fi/files/pdf/SpielmansParry.pdf\|From Evidence-based Medicine to Marketing-based Medicine: Evidence from Internal Industry Documents.]] 2010. //Journal of Bioethical Inquiry//.)) Publication or reporting bias, or the tendency not to publish negative results, increases the likelihood that the literature's descriptions of a therapy's efficacy are erroneous and decreases the likelihood that adverse effects are fully reported.(({{pmid>long:20388211}}))
-	- According to a [[http://www.bmj.com/cgi/content/extract/339/sep15_2/b3779\|2009 BMJ article]] chronicling a conference presentation, researchers, like politicians, use "spin" in presenting their results. This is the case of studies with both non-significant and significant results.	+	- According to a [[https://www.bmj.com/cgi/content/extract/339/sep15_2/b3779\|2009 BMJ article]] chronicling a conference presentation, researchers, like politicians, use "spin" in presenting their results. This is the case of studies with both non-significant and significant results.
-	-Smaller-sized studies are often published without the necessary statistical power to prove the validity of an observation or therapy. For example, an article in 1994 reported that a variant of the Vitamin D Receptor gene explains most of the population's risk for having low bone-mineral density.(({{pubmed>long:8161378}})) The finding made the cover page of //Nature//, heralding the "osteoporosis gene." Other subsequent studies showed an opposite effect, with the same variant predisposing to stronger bones. A large-scale analysis, of 100-fold more participants than the original //Nature// study, showed that there is no effect at all.(({{pubmed>long:11204438}}))	+	-Smaller-sized studies are often published without the necessary statistical power to prove the validity of an observation or therapy. For example, an article in 1994 reported that a variant of the Vitamin D Receptor gene explains most of the population's risk for having low bone-mineral density.(({{pmid>long:8161378}})) The finding made the cover page of //Nature//, heralding the "osteoporosis gene." Other subsequent studies showed an opposite effect, with the same variant predisposing to stronger bones. A large-scale analysis, of 100-fold more participants than the original //Nature// study, showed that there is no effect at all.(({{pmid>long:11204438}}))
-	-In some fields, the reverence for experts and expert opinion has fostered [[http://www.nytimes.com/2007/10/09/science/09tier.html\|mistaken consensus]], even while successful cures for chronic disease remain elusive.	+	-In some fields, the reverence for experts and expert opinion has fostered [[https://www.nytimes.com/2007/10/09/science/09tier.html\|mistaken consensus]], even while successful cures for chronic disease remain elusive.
	-Peer review has had the effect of validating popular theories to the detriment of novel and/or contradictory theories.		-Peer review has had the effect of validating popular theories to the detriment of novel and/or contradictory theories.
	-Therapeutic interventions, for which there is a [[home:publications:albert_autoimmunity_reviews_2009\|short-term benefit but long-term harm]], are not accurately represented in studies over shorter time windows. [[home:pathogenesis:vitamind:longterm\|Insufficient follow-up]] is particularly problematic in studies looking at vitamin D and other immunosuppressants. Successful treatments must be [[home:patients:assessing_literature:palliative\|curative, not palliative]].		-Therapeutic interventions, for which there is a [[home:publications:albert_autoimmunity_reviews_2009\|short-term benefit but long-term harm]], are not accurately represented in studies over shorter time windows. [[home:pathogenesis:vitamind:longterm\|Insufficient follow-up]] is particularly problematic in studies looking at vitamin D and other immunosuppressants. Successful treatments must be [[home:patients:assessing_literature:palliative\|curative, not palliative]].
-	-Many of the articles that appear in scientific journals, under the bylines of prominent academics, are actually written by ghostwriters, who are paid by drug companies.(({{pubmed>long:16506304}})) These seemingly objective articles, which doctors around the world use to guide their care of patients, are often part of a marketing campaign by companies to promote a product or play up the condition it treats. One recent and prominent example relates to the way studies supporting HRT were [[http://www.nytimes.com/2009/08/05/health/research/05ghost.html?_r=1&emc=eta1\|written by ghostwriters]].	+	-Many of the articles that appear in scientific journals, under the bylines of prominent academics, are actually written by ghostwriters, who are paid by drug companies.(({{pmid>long:16506304}})) These seemingly objective articles, which doctors around the world use to guide their care of patients, are often part of a marketing campaign by companies to promote a product or play up the condition it treats. One recent and prominent example relates to the way studies supporting HRT were [[https://www.nytimes.com/2009/08/05/health/research/05ghost.html?_r=1&emc=eta1\|written by ghostwriters]].
-	- As was illustrated by a 2009 survey of 838 marketed drugs, the available genotoxicity and carcinogenicity data for these drugs is inconsistent.(({{pubmed>long:18845271}})) Of these 838 drugs, 366 (43.7%) did not have such data.	+	- As was illustrated by a 2009 survey of 838 marketed drugs, the available genotoxicity and carcinogenicity data for these drugs is inconsistent.(({{pmid>long:18845271}})) Of these 838 drugs, 366 (43.7%) did not have such data.
-	- According to Henry H. Q. Heng's 2008 //JAMA// commentary, there may be limits of experimental medical science at the current level of our understanding, which is likely much more primitive than most of us like to think. Similar to repairing a clock in which each broken part is fixed in order, investigators have attempted to discover causal relationships among key components of an individual and to treat those components accordingly. As a result of the over-reliance on reductionist approaches, doctors recommend therapies for which we lack full pathophysiological understanding.(({{pubmed>long:18827215}}))	+	- According to Henry H. Q. Heng's 2008 //JAMA// commentary, there may be limits of experimental medical science at the current level of our understanding, which is likely much more primitive than most of us like to think. Similar to repairing a clock in which each broken part is fixed in order, investigators have attempted to discover causal relationships among key components of an individual and to treat those components accordingly. As a result of the over-reliance on reductionist approaches, doctors recommend therapies for which we lack full pathophysiological understanding.(({{pmid>long:18827215}}))
	- As described in the section, [[home:pathogenesis:successive_infection?&#disease_is_a_continuum\|Disease is a continuum]], it is common practice to assign one group of patients participating in a controlled trial to be the “healthy control group.” While researchers are apt to make a hard distinction between health and disease, this dichotomy is contrary to what we know about successive infection. The process of successive infection does not just occur in sick people or people who are symptomatic. In healthy subjects, subclinical infection is not the exception, but the rule. From even before birth, every human is constantly acquiring new microbes.		- As described in the section, [[home:pathogenesis:successive_infection?&#disease_is_a_continuum\|Disease is a continuum]], it is common practice to assign one group of patients participating in a controlled trial to be the “healthy control group.” While researchers are apt to make a hard distinction between health and disease, this dichotomy is contrary to what we know about successive infection. The process of successive infection does not just occur in sick people or people who are symptomatic. In healthy subjects, subclinical infection is not the exception, but the rule. From even before birth, every human is constantly acquiring new microbes.
-	- Corrections come slowly if at all according to a [[http://www.esajournals.org/doi/pdf/10.1890/ES10-00142.1\|March 2011 paper]] looking at a papers published in Nature or Science and since rebutted (described [[http://scholarlykitchen.sspnet.org/2011/07/21/is-something-fishy-going-on-citations-suggest-correction-comes-slowly-if-it-comes-at-all/\|here]]. According to the authors:	+	- Corrections come slowly if at all according to a [[https://www.esajournals.org/doi/pdf/10.1890/ES10-00142.1\|March 2011 paper]] looking at a papers published in Nature or Science and since rebutted (described [[https://scholarlykitchen.sspnet.org/2011/07/21/is-something-fishy-going-on-citations-suggest-correction-comes-slowly-if-it-comes-at-all/\|here]]. According to the authors:


Line 59:		Line 59: